samedan logo
 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Discussing developments on Highly Potent APIs with industry expert, Richard Arnett for the HPAPI USA conference 2019

SMI Group

SMI Reports: Exclusive interview with industry expert, Richard Arnett Manager, Industrial Hygiene, Pharmascience for the HPAPI USA conference 2019

Ahead of the 2019 HPAPI USA Conference taking place in Boston on 21st – 22nd October, SMi caught up with Richard Arnett, Manager, Industrial Hygiene, Pharmascience who is speaking on Day Two of the agenda. Richard shared his thoughts on how the industry has developed and briefly touched on what he will be discussing in October.

Snapshot of Richard’s Interview:

What key differences have you noticed in the last year regarding significant developments in Highly Potent APIs?
“Three main points: Higher potency, particularly for OSD products Lower ADE, often poorly soluble and tougher to clean APIs Closer scrutiny by regulatory agencies. For example Health Canada is now more closely aligned with the EMA and there’s now a more harmonised approach, with a mutual recognition agreement in place which sets the bar to the appropriate level, not just with the regs/GMP’s, but also through compliance/enforcement ensuring that the appropriate controls are in place to mitigate cross-contamination risks…”

What do you see as the greatest challenge for you to overcome personally in the Highly Potent API field currently?
“Changing the culture from traditional ‘open processes’ to closed processing with reduced reliance on PPE & thus reduced worker-product exposure risk. I often hear ‘what’s the risk – the workers are wearing respirators’– and there remains a perception that this is adequate… But what about when the airborne concentration might exceed the assigned protection factor of the respirators? Or what about the exposure risk when the respirators are removed?...”

Richard will be joined at the conference by a number of key figures in the HPAPI industry including Rakesh Dixit, Vice President of R&D Global Head, MedImmune; Vice President of R&D Translational Sciences – Biologics Safety Assessment, AstraZeneca; Janet Gould, Senior Managing Toxicologist, SafeBridge Consultants USA and many more.

For the full speaker interview, event details and speaker line-up, visit www.hpapi-usa.com/PR6

Proudly Sponsored by BSP Pharmaceuticals | LONZA | Minakem | SafeBridge Consultants

Highly Potent Active Pharmaceutical Ingredients USA
Conference: October 21st – 22nd
Workshops: October 23rd
Venue: Sheraton Boston Hotel, USA

For sponsorship, exhibition and branding enquiries, please contact Alia Malick on +44 (0)20 7827 6168 or amalick@smi-online.co.uk

For media enquiries contact Neill Howard on Tel: +44 (0)20 7827 6164 or nhoward@smi-online.co.uk

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
phone +44 (0)20 7827 6000
email events@smi-online.co.uk
web smi-online.co.uk/
email London
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Colorcon, Inc. Launches Nutrafinish® Label Friendly Tablet Coatings for Nutritional Supplements Market

Harleysville, Pennsylvania, USA, 23rd February 2021 - Colorcon, a world leader in the development and supply of film coating systems and excipients, today announces the expansion of its Nutrafinish® Film Coatings portfolio to include Label Friendly and TiO2-Free coating products for the nutritional and dietary supplements market.
More info >>


White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

Industry Events

Pharma Integrates 2021

16 November 2021, VIRTUAL CONFERENCE

Now in its tenth year, Pharma Integrates is a unique event bringing together pharma and healthcare leaders across the Pharmaceutical pipeline to address their needs, to share insights and create debate on crucial topics that influence the future of patient outcomes.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement